Company Analysis
Sign in

Alto Neuroscience Inc. (ANRO)

NYSE: ANRO · Pharmaceutical Preparations · Mountain View, CA · filing with the SEC since 2023
Full chart Alerts Compare
Grade5.2
◀ Past 4.6● Present 4.5▶ Future 6.3
7 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income-$63.2M-2.9%
Earnings per share$-2.19+12.4%
Operating cash flow-$51.8M-9.2%
Cash$177M+4.9%
Debt$16.2M+57.7%
Shareholders’ equity$151M-0.2%
Shares, diluted28.9M+17.3%
Return on equity-41.8%
The recordfrom its filings
Filings in 202662
Newest filingNov 10 · 10-Q
Annual reportMar 16, 2026
Quarterly reportNov 10, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$3.6M
Insider buys, 12 months$0.00
Patents granted3
Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Trailing twelve months to Sep 2026Net income -$95.2MCash from operations -$79.1Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
232425
As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 10, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Oct 30, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Oct 5, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 1, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Aug 27, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton ANRO · research, not advice